Factor VII

What is Factor VII?

Factor VII, also known as proconvertin, is a vital plasma protein that plays a crucial role in the body's natural blood clotting process. It is a serine protease, which means it's an enzyme that helps break down proteins. In its active form, Factor VIIa, it initiates the extrinsic pathway of the **coagulation cascade**, a complex series of events that leads to the formation of a stable blood clot. This protein is naturally produced in the liver, and its synthesis is dependent on Vitamin K.

For therapeutic purposes, especially in managing certain **bleeding disorders**, a genetically engineered version called **recombinant Factor VIIa** (rFVIIa) is often used. This synthetic form functions identically to the activated human Factor VII, providing a targeted approach to control severe and life-threatening bleeding episodes. Its development has been a significant advancement in the treatment of patients who cannot be effectively managed with traditional factor replacement therapies.

How Does it Work?

The primary function of activated Factor VII (Factor VIIa) is to initiate the extrinsic pathway of blood coagulation. When there is an injury to a blood vessel, tissue factor (TF) is exposed. Factor VIIa binds to this exposed tissue factor, forming a potent enzyme complex (TF-FVIIa). This complex then activates Factor X to Factor Xa and, to a lesser extent, Factor IX to Factor IXa.

The generation of Factor Xa is a critical step, as Factor Xa, in turn, converts prothrombin to thrombin. Thrombin then catalyzes the conversion of fibrinogen to fibrin, which forms the meshwork of a blood clot, effectively stopping blood loss. What makes therapeutic Factor VIIa particularly valuable is its ability to directly activate Factor X on the surface of activated platelets, even in the absence of Factor VIII or Factor IX. This 'bypassing' mechanism is crucial for patients with hemophilia who have developed inhibitors against standard factor replacement treatments, allowing for effective **hemostasis** (the process of stopping bleeding).

Medical Uses

The therapeutic application of Factor VII (specifically recombinant Factor VIIa) is primarily focused on managing and preventing bleeding episodes in individuals with specific clotting deficiencies or severe bleeding conditions. Key medical uses include:

• Hemophilia A or B with Inhibitors: This is a primary indication. Patients with hemophilia who develop antibodies (inhibitors) against infused Factor VIII or Factor IX can no longer be treated effectively with standard replacement therapy. Factor VIIa provides a bypass mechanism to achieve hemostasis.
• Congenital Factor VII Deficiency: For individuals born with a deficiency in Factor VII, recombinant Factor VIIa can be used to treat or prevent bleeding.
• Acquired Hemophilia: A rare autoimmune disorder where the body develops inhibitors against its own Factor VIII. Factor VIIa can be used to control bleeding in these patients.
• Glanzmann's Thrombasthenia: A rare inherited platelet disorder characterized by impaired platelet aggregation. Factor VIIa may be used in patients who are refractory to platelet transfusions.
• Severe Perioperative Bleeding: In some critical surgical settings or trauma cases where severe, uncontrolled bleeding occurs and conventional methods are insufficient, Factor VIIa may be used off-label to achieve hemostasis, particularly in patients with complex coagulopathies.

Dosage

The dosage of Factor VII (recombinant Factor VIIa) is highly individualized and depends on several factors, including the patient's weight, the severity and location of the bleeding episode, the underlying condition, and the patient's response to treatment. It is administered intravenously (into a vein).

For patients with hemophilia A or B with inhibitors, common initial doses range from 90 to 120 mcg/kg, administered every 2 to 6 hours until hemostasis is achieved. The frequency and duration of administration are adjusted based on clinical observation and laboratory parameters. For other indications, dosing regimens may vary significantly. Due to the critical nature of its use and the potential for serious side effects, Factor VIIa administration must always be guided and monitored by a healthcare professional experienced in treating coagulation disorders.

Side Effects

While generally well-tolerated, Factor VII therapy can be associated with certain side effects. It's important to weigh the benefits of controlling severe bleeding against the potential risks.

Common Side Effects:

• Fever
• Headache
• Nausea
• Vomiting
• Injection site reactions (e.g., pain, redness)
• Rash

Serious Side Effects:

The most significant concern with Factor VIIa is the potential for thromboembolic events, given its procoagulant nature. These can include:

• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Myocardial Infarction (heart attack)
• Stroke
• Disseminated Intravascular Coagulation (DIC)

These serious events are more likely in patients with underlying risk factors for thrombosis. Additionally, hypersensitivity or allergic reactions, including anaphylaxis, can occur, although they are rare. Patients should be monitored closely for any signs of allergic reactions or thrombotic complications during and after administration.

Drug Interactions

Patients receiving Factor VII should be carefully monitored for potential drug interactions, especially with other medications that affect blood coagulation. The most notable interaction is with antifibrinolytic agents, such as tranexamic acid or aminocaproic acid. Concurrent use of Factor VIIa with these drugs may increase the risk of thrombotic events due to their combined procoagulant effects. While sometimes used together in specific clinical scenarios, this combination requires careful consideration and close monitoring by a physician.

Caution is also advised when Factor VIIa is used with other procoagulant factors or drugs that enhance coagulation, as this could further elevate the risk of thrombosis. Always inform your healthcare provider about all medications, supplements, and herbal products you are currently taking before starting Factor VIIa therapy.

FAQ

What is the difference between Factor VII and Factor VIIa?

Factor VII is the inactive precursor protein. Factor VIIa is the activated form of Factor VII, which is the therapeutically active component used in medications. Recombinant Factor VIIa (rFVIIa) is the synthetic version.

How is Factor VII administered?

Factor VIIa is administered intravenously (into a vein) by a healthcare professional.

Can Factor VII be used for any type of bleeding?

While a powerful hemostatic agent, Factor VIIa is primarily indicated for specific bleeding disorders like hemophilia with inhibitors, congenital Factor VII deficiency, and Glanzmann's thrombasthenia. Its use in other severe bleeding situations is typically off-label and reserved for critical cases where other treatments have failed.

What should I do if I miss a dose?

Factor VIIa is typically administered in a hospital or clinical setting under strict medical supervision for acute bleeding episodes. Dosing schedules are determined by the treating physician, and any missed doses would be managed directly by the medical team.

Products containing Factor VII are available through trusted online pharmacies. You can browse Factor VII-based medications at ShipperVIP or Medicenter.

Summary

Factor VII, particularly its recombinant activated form (Factor VIIa), represents a critical therapeutic option for individuals suffering from severe bleeding episodes, especially those with specific **blood coagulation factor** deficiencies or inhibitory antibodies. By effectively bypassing certain parts of the **coagulation cascade**, it facilitates rapid and robust clot formation, offering a lifeline in situations where traditional treatments are ineffective.

While highly effective in achieving **hemostasis** and controlling life-threatening bleeds, its use requires careful medical supervision due to the potential for serious side effects, primarily thromboembolic events. Understanding its mechanism of action, appropriate medical uses, dosage considerations, and potential risks is paramount for safe and effective patient management. As a specialized treatment, Factor VIIa continues to play an indispensable role in modern hematology and critical care medicine.